Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma
- PMID: 3100623
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma
Abstract
Tumor-infiltrating lymphocytes from six patients with metastatic malignant melanoma were expanded by culture in recombinant interleukin 2. Three of the preparations were highly cytotoxic against autologous fresh melanoma tumor cells, but not against autologous fresh normal cells or allogeneic fresh tumor targets. The other three were highly cytotoxic against autologous fresh melanoma tumor cells and also had a limited capacity to kill allogeneic fresh tumor targets. The tumor-associated specific killer cells could be expanded from threefold to 95,652-fold with maintenance of specific antitumor lysis. The expanded tumor-infiltrating cells were Leu-4+ T cells, and in five of six patients the majority were Leu-3+. These studies demonstrate that the melanoma-bearing patient raises an immune response against autologous tumor and presents a method for the generation of human lymphocytes with antitumor reactivity that may be useful in the adoptive immunotherapy of tumors.
Similar articles
-
Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2.Int J Cancer. 1981 Dec;28(6):695-703. doi: 10.1002/ijc.2910280607. Int J Cancer. 1981. PMID: 6977498
-
Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.J Immunol. 1989 Nov 15;143(10):3404-11. J Immunol. 1989. PMID: 2509557
-
Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.Cancer Res. 1988 Jan 1;48(1):206-14. Cancer Res. 1988. PMID: 3257161
-
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.J Exp Med. 1982 Jun 1;155(6):1823-41. doi: 10.1084/jem.155.6.1823. J Exp Med. 1982. PMID: 6176669 Free PMC article.
-
Human autologous tumor-specific T cells in malignant melanoma.Cancer Metastasis Rev. 1991 Jun;10(2):151-76. doi: 10.1007/BF00049412. Cancer Metastasis Rev. 1991. PMID: 1873855 Review.
Cited by
-
Immune correlates of melanoma survival in adoptive cell therapy.Oncoimmunology. 2013 Feb 1;2(2):e22889. doi: 10.4161/onci.22889. Oncoimmunology. 2013. PMID: 23525606 Free PMC article.
-
Innate Immune Cells in Melanoma: Implications for Immunotherapy.Int J Mol Sci. 2024 Aug 5;25(15):8523. doi: 10.3390/ijms25158523. Int J Mol Sci. 2024. PMID: 39126091 Free PMC article. Review.
-
Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.Immunol Res. 1990;9(4):298-313. doi: 10.1007/BF02935529. Immunol Res. 1990. PMID: 2089075 Review. No abstract available.
-
In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.Cancer Immunol Immunother. 1992;35(4):289-95. doi: 10.1007/BF01789337. Cancer Immunol Immunother. 1992. PMID: 1387344 Free PMC article.
-
Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future.Diseases. 2016 Feb 15;4(1):10. doi: 10.3390/diseases4010010. Diseases. 2016. PMID: 28933390 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical